idiopathic pulmonary fibrosis

News

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

News

PureTech launches lung disease specialist Celea

PureTech launches Celea Therapeutics, tasked with bringing forward a drug that could offer a 'step change' in pulmonary fibrosis treatment.

News

Pliant slumps on decision to pause lung disease drug trial

Shares in Pliant plunged after the US biotech revealed that a safety signal led it to pause a trial of its idiopathic pulmonary fibrosis drug.

News

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O

Patients

pharmaphorum podcast Episode 147a featuring Farrell Simon

Chronic cough and the patient voice

Chronic cough impacts up to 10% of the adult population and has a physical, psychological, and social impact on patients’ lives.

News

ATS: Vicore, Endeavor therapies show promise in IPF

Two experimental therapies from Vicore Pharma and Endeavor BioMedicines that could provide new ways of treating idiopathic pulmonary fibrosis (IPF) have shown encouraging

Boehringer bags FDA okay for new pulmonary fibrosis drug

PureTech launches lung disease specialist Celea

Pliant slumps on decision to pause lung disease drug trial

Trial sets up filings for Boehringer IPF drug nerandomilast

Chronic cough and the patient voice

ATS: Vicore, Endeavor therapies show promise in IPF

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

idiopathic pulmonary fibrosis

Editor's Picks